The PI Group has acquired shares in the startup company 'CapCo Bio GmbH' in Freiburg and is now its largest shareholder. The company, founded in 2020, had presented its business model at a pitch in Freiburg organized by our subsidiary Push4Impact.
The technology of CapCo Bio, already verified with two exclusive patents and with a further three in the pipeline, is used to transport medically effective molecules to target cells in the human body via nano capsules. The nano capsules are non-toxic and are broken down residue-free. Fields of application range from new vaccinations to the medication of cancer and rare illnesses, to cell and gene therapy. Push4Impact will support CapCo Bio with further business development.
Push4Impact is the successor to PI Innovation GmbH. In 2022, the PI shareholders modified the business purpose, clearly differentiating it from Corporate Research. In the past few years, PI Innovation had already discovered many interesting business models outside of PI's fields of business. However, these business models often lacked the maturity necessary to be pursued further by PI Innovation, and they were also not responsible for this.
In order to make these innovations accessible to both us and to independent investors, in 2022, we founded Push4Impact as an incubator for new business models outside of the PI Group. This is leading to an individual, and, in the future, absolutely lucrative business model for Push4Impact.
For the PI Group, investing in CapCo Bio, the young spin-off company from the university of Freiburg, marks the entry into a new field of business with immense potential for innovation and growth. Further investments are in progress.
Contact persons:
- Markus Spanner, Chief Executive Officer PI Gruppe
- Luzius Amelung, Geschäftsführer Push4Impact